In the subgroup analyses, we found no significant differences between the survival curves of different genders (male vs. female), different tumor histological types (squamous cell carcinoma vs. adenocarcinoma), different PD‐L1 expression (positive vs. negative), and different immunotherapy regimens (tislelizumab vs. nivolumab vs. pembrolizumab) (Figure 7). This evidence concerns the gene CD274 and neoplasm.